Get the Stockscreener App
0.7636
7.53%
0.0535
Mira Pharmaceuticals Inc stock is traded at $0.7636, with a volume of 116.71K.
It is up +7.53% in the last 24 hours and down -16.70% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.7101
Open:
$0.72
24h Volume:
116.71K
Relative Volume:
1.22
Market Cap:
$32.09M
Revenue:
-
Net Income/Loss:
$-31.37M
P/E Ratio:
-0.531
EPS:
-1.438
Net Cash Flow:
$-4.23M
1W Performance:
-2.13%
1M Performance:
-16.70%
6M Performance:
-35.83%
1Y Performance:
-45.46%
1-Day Range:
$0.72
$0.82
1-Week Range:
$0.7101
$0.82
52-Week Range:
$0.60
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.7636 | 29.84M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,255.40 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.24 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.96 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.55 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.86 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelDouble Bottom - vinanet.vn
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineUpward Estimate Revision - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives 9.36% Stock GainSegment Revenue Breakdown - vinanet.vn
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue Stage - vinanet.vn
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Q3 2025 Earnings: EPS Beat on Narrower Loss Highlights Cost DisciplinePost-Announcement Reaction - vinanet.vn
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineEBITDA Margin Trends - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Q3 2025 Earnings: EPS Surprise of 26.47% on Narrowed Loss Despite No RevenueEarnings Miss Alert - vinanet.vn
MIRA|Mira Pharmaceuticals Inc|Price:0.764|Chg%:-0.025 - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
MIRA Q3 2025 Earnings: Narrower-than-expected Loss Amid Pre-Revenue PhaseConsensus Miss Rate - vinanet.vn
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
MIRA Q3 2025 Earnings: Narrower-than-Expected Net Loss Highlights Cost ManagementPositive Surprise Momentum - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):